%0 Journal Article
%A Traub, Jan
%A Otto, Markus
%A Sell, Roxane
%A Homola, György A
%A Steinacker, Petra
%A Oeckl, Patrick
%A Morbach, Caroline
%A Frantz, Stefan
%A Pham, Mirko
%A Störk, Stefan
%A Stoll, Guido
%A Frey, Anna
%T Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure.
%J ESC heart failure
%V 9
%N 4
%@ 2055-5822
%C Chichester
%I Wiley
%M DZNE-2022-01083
%P 2626-2634
%D 2022
%X Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF.Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1
%K Aged
%K Atrophy
%K Biomarkers
%K Female
%K Glial Fibrillary Acidic Protein: metabolism
%K Heart Failure: complications
%K Heart Failure: diagnosis
%K Humans
%K Male
%K Memory Disorders: diagnosis
%K Memory Disorders: etiology
%K Middle Aged
%K Prospective Studies
%K Brain atrophy (Other)
%K Chronic heart failure (Other)
%K Cognitive decline (Other)
%K GFAP (Other)
%K Glial fibrillary acidic protein (Other)
%K Memory dysfunction (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%2 pmc:PMC9288738
%$ pmid:35611842
%R 10.1002/ehf2.13986
%U https://pub.dzne.de/record/164534